JPWO2021170109A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021170109A5 JPWO2021170109A5 JP2022551553A JP2022551553A JPWO2021170109A5 JP WO2021170109 A5 JPWO2021170109 A5 JP WO2021170109A5 JP 2022551553 A JP2022551553 A JP 2022551553A JP 2022551553 A JP2022551553 A JP 2022551553A JP WO2021170109 A5 JPWO2021170109 A5 JP WO2021170109A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- difluorobenzyl
- indazol
- benzamide
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-((1-((2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)methyl)azetidin-3-yl)methyl)piperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide Chemical compound 0.000 claims 22
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- QFJRNHWITCOYTM-UHFFFAOYSA-N C(C1=CC=2C(=O)N(C(=O)C=2C=C1)C1C(=O)NC(=O)CC1)N1CCC(CC1)N1CCN(CC1)C1=CC=C(C(=O)NC=2C3=CC(CC4=CC(=CC(=C4)F)F)=CC=C3NN=2)C(NC2CCOCC2)=C1 Chemical compound C(C1=CC=2C(=O)N(C(=O)C=2C=C1)C1C(=O)NC(=O)CC1)N1CCC(CC1)N1CCN(CC1)C1=CC=C(C(=O)NC=2C3=CC(CC4=CC(=CC(=C4)F)F)=CC=C3NN=2)C(NC2CCOCC2)=C1 QFJRNHWITCOYTM-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- QRPAHVGMUMOIKN-UHFFFAOYSA-N O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C(C1)CC1(CC1)CN1C(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C(C1)CC1(CC1)CN1C(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 QRPAHVGMUMOIKN-UHFFFAOYSA-N 0.000 claims 1
- KMSVJJXKUAZDSE-UHFFFAOYSA-N O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C(CC1)CCN1C(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C(CC1)CCN1C(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 KMSVJJXKUAZDSE-UHFFFAOYSA-N 0.000 claims 1
- YCPLUHIVFNQIAA-UHFFFAOYSA-N O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C1CN(CC(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CCC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C(NC1CCOCC1)=C1)=CC=C1N(CC1)CCN1C1CN(CC(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CCC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 YCPLUHIVFNQIAA-UHFFFAOYSA-N 0.000 claims 1
- IOEDKYXHTFGJII-UHFFFAOYSA-N O=C(C(C(NC1CCOCC1)=C1)=CC=C1N1CCN(CC(C2)OCCN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C(NC1CCOCC1)=C1)=CC=C1N1CCN(CC(C2)OCCN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 IOEDKYXHTFGJII-UHFFFAOYSA-N 0.000 claims 1
- WVCMDDNYBQWYHE-UHFFFAOYSA-N O=C(C(C(NCCF)=C1)=CC=C1N1CCN(CC(C2)CN2C(C=C2)=CC(C(N3C(CCC(N4)=O)C4=O)=O)=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C(NCCF)=C1)=CC=C1N1CCN(CC(C2)CN2C(C=C2)=CC(C(N3C(CCC(N4)=O)C4=O)=O)=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 WVCMDDNYBQWYHE-UHFFFAOYSA-N 0.000 claims 1
- WWZSCXKSVMAKTD-UHFFFAOYSA-N O=C(C(C=C1)=CC=C1N1CCN(CC(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C=C1)=CC=C1N1CCN(CC(C2)CN2C(C=C2C(N3C(CCC(N4)=O)C4=O)=O)=CC=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 WWZSCXKSVMAKTD-UHFFFAOYSA-N 0.000 claims 1
- CIGKQAWSXVQMGA-UHFFFAOYSA-N O=C(C(C=C1)=CC=C1N1CCN(CCNC(C=C2)=CC(C(N3C(CCC(N4)=O)C4=O)=O)=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 Chemical compound O=C(C(C=C1)=CC=C1N1CCN(CCNC(C=C2)=CC(C(N3C(CCC(N4)=O)C4=O)=O)=C2C3=O)CC1)NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12 CIGKQAWSXVQMGA-UHFFFAOYSA-N 0.000 claims 1
- DGQYLRDJYAWVJG-UHFFFAOYSA-N O=C(CNC(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)N(CC1)CCN1C(C=C1)=CC=C1C(NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12)=O Chemical compound O=C(CNC(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)N(CC1)CCN1C(C=C1)=CC=C1C(NC1=NNC2=CC=C(CC3=CC(F)=CC(F)=C3)C=C12)=O DGQYLRDJYAWVJG-UHFFFAOYSA-N 0.000 claims 1
- PHJNHVUVPFJGMV-UHFFFAOYSA-N O=C(CNC(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)N(CC1)CCN1C1=CC=C(C(NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)=O)C(NCCF)=C1 Chemical compound O=C(CNC(C=C1)=CC(C(N2C(CCC(N3)=O)C3=O)=O)=C1C2=O)N(CC1)CCN1C1=CC=C(C(NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)=O)C(NCCF)=C1 PHJNHVUVPFJGMV-UHFFFAOYSA-N 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 102000005937 Tropomyosin Human genes 0.000 claims 1
- 108010030743 Tropomyosin Proteins 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020076748 | 2020-02-26 | ||
CNPCT/CN2020/076748 | 2020-02-26 | ||
PCT/CN2021/078240 WO2021170109A1 (en) | 2020-02-26 | 2021-02-26 | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023514872A JP2023514872A (ja) | 2023-04-11 |
JPWO2021170109A5 true JPWO2021170109A5 (ru) | 2024-03-04 |
Family
ID=77490737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022551553A Pending JP2023514872A (ja) | 2020-02-26 | 2021-02-26 | トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230257380A1 (ru) |
EP (1) | EP4110772A4 (ru) |
JP (1) | JP2023514872A (ru) |
KR (1) | KR20230010070A (ru) |
CN (1) | CN115697989A (ru) |
AU (1) | AU2021225981A1 (ru) |
BR (1) | BR112022016901A2 (ru) |
CA (1) | CA3173262A1 (ru) |
IL (1) | IL295799A (ru) |
MX (1) | MX2022010465A (ru) |
WO (1) | WO2021170109A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
CA3110267A1 (en) * | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
WO2022161414A1 (zh) * | 2021-01-26 | 2022-08-04 | 成都茵创园医药科技有限公司 | 芳香化合物、含其的药物组合物及其应用 |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
WO2023036175A1 (zh) * | 2021-09-08 | 2023-03-16 | 南京明德新药研发有限公司 | 戊二酰亚胺类化合物与其应用 |
WO2023055952A1 (en) * | 2021-09-29 | 2023-04-06 | C4 Therapeutics, Inc. | Neurotrophic tyrosine receptor kinase (ntrk) degrading compounds |
WO2023066350A1 (zh) * | 2021-10-22 | 2023-04-27 | 标新生物医药科技(上海)有限公司 | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 |
EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
WO2023116835A1 (zh) * | 2021-12-24 | 2023-06-29 | 苏州开拓药业股份有限公司 | 一种具有酰亚胺骨架的多蛋白降解剂 |
TW202333670A (zh) * | 2022-01-04 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用 |
WO2023193760A1 (en) * | 2022-04-06 | 2023-10-12 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
US20230416240A1 (en) * | 2022-06-16 | 2023-12-28 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
CN117510504A (zh) * | 2022-08-05 | 2024-02-06 | 深圳市新樾生物科技有限公司 | 蛋白激酶降解剂、药物及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015247817C1 (en) * | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
EP3233840B1 (en) * | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
CA2979070A1 (en) * | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197051A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
KR102538307B1 (ko) * | 2017-12-13 | 2023-05-31 | 상하이테크 유니버시티 | Alk 단백질 분해제 및 암 치료에서의 이의 용도 |
CA3110267A1 (en) * | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
-
2021
- 2021-02-26 JP JP2022551553A patent/JP2023514872A/ja active Pending
- 2021-02-26 BR BR112022016901A patent/BR112022016901A2/pt unknown
- 2021-02-26 MX MX2022010465A patent/MX2022010465A/es unknown
- 2021-02-26 WO PCT/CN2021/078240 patent/WO2021170109A1/en unknown
- 2021-02-26 US US17/904,822 patent/US20230257380A1/en active Pending
- 2021-02-26 IL IL295799A patent/IL295799A/en unknown
- 2021-02-26 EP EP21760113.7A patent/EP4110772A4/en active Pending
- 2021-02-26 AU AU2021225981A patent/AU2021225981A1/en active Pending
- 2021-02-26 KR KR1020227033274A patent/KR20230010070A/ko unknown
- 2021-02-26 CA CA3173262A patent/CA3173262A1/en active Pending
- 2021-02-26 CN CN202180031506.7A patent/CN115697989A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
JP2011515462A5 (ru) | ||
JP2014511869A5 (ru) | ||
RU2606497C2 (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
JP2019077725A5 (ru) | ||
JP2020503299A5 (ru) | ||
JP2009541268A5 (ru) | ||
JP2009526072A5 (ru) | ||
JP5938038B2 (ja) | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 | |
JP2014525444A5 (ru) | ||
JP2017510555A5 (ru) | ||
JPWO2021170109A5 (ru) | ||
JP2009525978A5 (ru) | ||
WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
JP2007519754A5 (ru) | ||
JP2019505595A5 (ru) | ||
JP2015531773A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
JP2008513500A5 (ru) | ||
JP2013510876A5 (ru) | ||
JP2012508223A5 (ru) | ||
JP2013517283A5 (ru) | ||
CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
JPWO2020038415A5 (ru) |